Mp53-06 Gustave Roussy Immune Score Predicts Survival Outcome of Patients With Metastatic Urothelial Carcinoma Treated With Pembrolizumab: A Multicenter Study of 321 Patients (Yushima Study)

You have accessJournal of UrologyBladder Cancer: Invasive V (MP53)1 May 2024MP53-06 GUSTAVE ROUSSY IMMUNE SCORE PREDICTS SURVIVAL OUTCOME OF PATIENTS WITH METASTATIC UROTHELIAL CARCINOMA TREATED WITH PEMBROLIZUMAB: A MULTICENTER STUDY OF 321 PATIENTS (YUSHIMA STUDY) Kenji Tanabe, Shuichiro Kobayashi, Katsushi Nagahama, Junji Yonese, Yukihiro Otsuka, Tetsuo Okuno, Ryoji Takazawa, Akira Noro, Masataka Yano, Tetsuro Tsukamoto, Kazutaka Saito, Yasuyuki Sakai, Fumitaka Koga, Yukio Kageyama, Hajime Tanaka, Soichiro Yoshida, and Yasuhisa Fujii Kenji TanabeKenji Tanabe , Shuichiro KobayashiShuichiro Kobayashi , Katsushi NagahamaKatsushi Nagahama , Junji YoneseJunji Yonese , Yukihiro OtsukaYukihiro Otsuka , Tetsuo OkunoTetsuo Okuno , Ryoji TakazawaRyoji Takazawa , Akira NoroAkira Noro , Masataka YanoMasataka Yano , Tetsuro TsukamotoTetsuro Tsukamoto , Kazutaka SaitoKazutaka Saito , Yasuyuki SakaiYasuyuki Sakai , Fumitaka KogaFumitaka Koga , Yukio KageyamaYukio Kageyama , Hajime TanakaHajime Tanaka , Soichiro YoshidaSoichiro Yoshida , and Yasuhisa FujiiYasuhisa Fujii View All Author Informationhttps://doi.org/10.1097/01.JU.0001008784.37684.bd.06AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Previous studies have reported several prognostic markers for patients with metastatic urothelial carcinoma (mUC) treated with pembrolizumab; however, established markers remain unavailable. The Gustave Roussy Immune Score (GRIm-Score) was reported to select patients for immune checkpoint inhibitor treatment and evaluated the scores usefulness as a prognostic marker in various carcinomas. This study aimed to evaluate various markers, including the GRIm-Score, to select patients with mUC who may gain survival benefits from pembrolizumab treatment. METHODS: This multicenter, retrospective study included 321 patients with mUC who were treated with pembrolizumab. The GRIm-Score was calculated based on the neutrophil-to-lymphocyte ratio (NLR), lactate dehydrogenase, and albumin. Patients with a GRIm-Score of ≥2 were categorized as the high GRIm group and those with a GRIm-Score of ≤1 as the low GRIm group. The association between clinical factors and overall survival (OS) was analyzed using the Cox proportional hazard model. The Time-dependent receiver operating characteristic (Td-ROC) curve was used to determine the prognostic values of the GRIm-Score and other markers. RESULTS: The median follow-up period after pembrolizumab initiation was 7.3 months. Throughout the study 215 (67%) patients died. The high GRIm group consisted of 88 (27%) patients. This group had females, higher Eastern Cooperative Oncology Group performance status (ECOG-PS), and higher C-reactive protein (CRP) and NLR (p=0.027, p<0.001, p<0.001, and p<0.001, respectively). The median OS was significantly shorter in the high GRIm group than in the low GRIm group (2.7 vs. 14.3 months, respectively; p<0.0001). Multivariate analysis revealed high GRIm-Score, ECOG-PS of ≥2, visceral metastases, and CRP of >0.36 as independent, poor prognostic factors. Td-ROC analysis for OS demonstrated that the GRIm-Score exhibited a higher prognostic value than other markers, including NLR (the areas under the curve of the GRIm-Score and NLR at 90 days were 0.794 and 0.726, respectively). CONCLUSIONS: The GRIm-Score is a useful prognostic marker for patients with mUC treated with pembrolizumab, and it may improve prognostic accuracy. Download PPT Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e864 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Kenji Tanabe More articles by this author Shuichiro Kobayashi More articles by this author Katsushi Nagahama More articles by this author Junji Yonese More articles by this author Yukihiro Otsuka More articles by this author Tetsuo Okuno More articles by this author Ryoji Takazawa More articles by this author Akira Noro More articles by this author Masataka Yano More articles by this author Tetsuro Tsukamoto More articles by this author Kazutaka Saito More articles by this author Yasuyuki Sakai More articles by this author Fumitaka Koga More articles by this author Yukio Kageyama More articles by this author Hajime Tanaka More articles by this author Soichiro Yoshida More articles by this author Yasuhisa Fujii More articles by this author Expand All Advertisement PDF downloadLoading ...